²é¿´: 886  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö LS-EPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

eveb

ľ³æ (ÕýʽдÊÖ)

[ÇóÖú] SCIÊÕ¼¼°ÒýÓòéѯ

×÷Õß:
Zhang B, Feng X, Wang J, Xu X, Lin N, Liu H.
ÎÄÌâ:
Combined antitumor effect of Ad-bFGF-siRNA and Ad-Vpr on the growth of xenograft glioma in nude mouse model.
ÆÚ¿¯Ãû,Äê·Ý,¾í(ÆÚ),ÆðÖ¹Ò³Âë:
Pathol Oncol Res. 2011 Jun;17(2):237-42.
È«ÎÄÁ´½Ó:
http://dx.doi.org/10.1007/s12253-010-9303-5
Êý¾Ý¿âÃû³Æ:
springer
ÊÕ¼ÐÅÏ¢:
ÇóÖú SCI ÊÕ¼ÐÅÏ¢
ÇóÖú±»Òý´ÎÊý
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

baiyuefei

°æÖ÷ (ÎÄѧ̩¶·)

·çÑ©

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

4Â¥2014-11-13 12:22:41
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 4 ¸ö»Ø´ð

baiyuefei

°æÖ÷ (ÎÄѧ̩¶·)

·çÑ©

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
eveb: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, thank 2014-11-13 12:27:03
jssxh: LS-EPI+1, лл²ÎÓ룬Çë¼ÌÐø¹Ø×¢±¾°æ¿é 2014-11-13 14:59:39
Combined Antitumor Effect of Ad-bFGF-siRNA and Ad-Vpr on the Growth of Xenograft Glioma in Nude Mouse Model


×÷Õß:Zhang, B (Zhang, Biao)[ 2 ] ; Feng, XQ (Feng, Xuequan)[ 3 ] ; Wang, JH (Wang, Jinhuan)[ 1 ] ; Xu, XN (Xu, Xinnu)[ 4 ] ; Lin, N (Lin, Na)[ 4 ] ; Liu, HS (Liu, Hongsheng)[ 4 ]




PATHOLOGY & ONCOLOGY RESEARCH



¾í: 17

ÆÚ: 2

Ò³: 237-242

DOI: 10.1007/s12253-010-9303-5

³ö°æÄê: JUN 2011

²é¿´ÆÚ¿¯ÐÅÏ¢




































ÕªÒª

Basic fibroblast growth factor (bFGF) has been demonstrated to correlate with glioma grade and clinical outcome and has established its possible usefulness as a target for glioma therapy. Vpr has been described as an antitumor agent and displays a potent antitumor nature. Here, we try to investigate whether a combined treatment with bFGF-siRNA and Vpr gene would have a enhanced effectiveness on glioma in vitro and in vivo.After treatments with only Ad-bFGF-siRNA, only Ad-Vpr, and a combination of both, we assessed the changes in cell proliferation, cell cycle, and apoptosis in vitro by the methods of MTT, PI and FITC-AnnexinV double staining, respevtively. In addition, we also evaluated the combined effect of bFGF-siRNA and Vpr gene therapy on glioma in vivo using xenograft glioma models in nude mice. Combined Ad-bFGF-siRNA and Ad-Vpr treatment was more better successful in inhibiting cell proliferation in comparison with treatments of either Ad-bFGF-siRNA or Ad-Vpr alone. Treatment of Ad-Vpr alone or a treatment of a combination of Ad-bFGF-siRNA and Ad-Vpr induced the G2/M cell cycle arrest and apoptosis; however, combined treatment was more effective than the Ad-Vpr treatment alone. Although each single treatment can slow the growth of xenograft glioma, the combined treatment with Ad-bFGF-siRNA and Ad-Vpr was better than either the Ad-bFGF-siRNA or Ad-Vpr treatment alone. Our results suggest that the combination therapy with bFGF-siRNA and Vpr gene can achieve a enhanced activity of anti-glioma, supporting the idea that the combination of these two antitumor agents could open new perspectives in glioma therapy.


¹Ø¼ü´Ê

×÷Õ߹ؼü´Ê:siRNA; bFGF; Vpr; Adenoviral vector

KeyWords Plus:IN-VIVO ELECTROPORATION; HIV-1 VPR; NUCLEAR ACCUMULATION; CELLS; GLIOBLASTOMA; INHIBITION; CASPASE-9; RECEPTOR; PLASMID; TUMORS


×÷ÕßÐÅÏ¢

ͨѶ×÷ÕßµØÖ·: Wang, JH (ͨѶ×÷Õß)



      

Tianjin Huan Hu Hosp, Dept Neurosurg, 122 Qixiangtai Rd, Tianjin 300060, Peoples R China.



µØÖ·:



      

[ 1 ] Tianjin Huan Hu Hosp, Dept Neurosurg, Tianjin 300060, Peoples R China



      

[ 2 ] Tianjin Huan Hu Hosp, Clin Lab, Tianjin 300060, Peoples R China



      

[ 3 ] Tianjin First Ctr Hosp, Dept Neurosurg, Tianjin 300192, Peoples R China



      

[ 4 ] Tianjin First Ctr Hosp, Key Lab Crit Care Med, Minist Hlth, Tianjin 300192, Peoples R China



µç×ÓÓʼþµØÖ·:wangjinhuanfch@yahoo.com.cn


»ù½ð×ÊÖúÖÂл



»ù½ð×ÊÖú»ú¹¹

ÊÚȨºÅ



National Natural Sciences Foundation of China


30672158

²é¿´»ù½ð×ÊÖúÐÅÏ¢   




³ö°æÉÌ

SPRINGER, VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS


Àà±ð / ·ÖÀà

Ñо¿·½Ïò:Oncology; Pathology

Web of Science Àà±ð:Oncology; Pathology


ÎÄÏ×ÐÅÏ¢

ÎÄÏ×ÀàÐÍ:Article

ÓïÖÖ:English

Èë²ØºÅ: WOS:000290587300007

PubMed ID: 20848251

ISSN: 1219-4956


ÆÚ¿¯ÐÅÏ¢


Impact Factor (Ó°ÏìÒò×Ó): Journal Citation Reports®


ÆäËûÐÅÏ¢

IDS ºÅ: 763VH

Web of Science ºËÐĺϼ¯ÖÐµÄ "ÒýÓõIJο¼ÎÄÏ×": 20

Web of Science ºËÐĺϼ¯ÖÐµÄ "±»ÒýƵ´Î": 5


ÒýÎÄÍøÂç




5 ±»ÒýƵ´Î

20 ÒýÓõIJο¼ÎÄÏ×

²é¿´ Related Records

²é¿´ÒýÖ¤¹ØÏµÍ¼

´´½¨ÒýÎĸú×Ù

(Êý¾ÝÀ´×Ô Web of ScienceTM ºËÐĺϼ¯)



È«²¿±»ÒýƵ´Î¼ÆÊý



5 / ËùÓÐÊý¾Ý¿â

5 / Web of Science ºËÐĺϼ¯

1 / BIOSIS Citation Index

0 / Öйú¿ÆÑ§ÒýÎÄÊý¾Ý¿â

0 / Data Citation Index

0 / SciELO Citation Index


×î½üµÄÒýÎÄ









Zhang, S. HIV-1 viral protein R downregulates Ebp1 and stabilizes p53 in glioblastoma U87MG cells. CLINICAL & TRANSLATIONAL ONCOLOGY, MAR 2014.



²é¿´È«²¿



´Ë¼Ç¼À´×Ô:

Web of ScienceTM ºËÐĺϼ¯


½¨ÒéÐÞÕý


Èç¹ûÏ£ÍûÌá¸ß´Ë¼Ç¼ÖÐÊý¾ÝµÄÖÊÁ¿£¬ÇëÌṩÐÞÕý½¨Òé¡£
2Â¥2014-11-13 12:21:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

baiyuefei

°æÖ÷ (ÎÄѧ̩¶·)

·çÑ©

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

Èë²ØºÅ: WOS:000290587300007
3Â¥2014-11-13 12:22:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 284Çóµ÷¼Á +13 Zhao anqi 2026-03-22 13/650 2026-03-25 09:51 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 292Çóµ÷¼Á +3 ¶ì¶ì¶ì¶î¶î¶î¶î¶ 2026-03-25 3/150 2026-03-25 07:45 by ms629
[¿¼ÑÐ] 281Çóµ÷¼Á +3 Koxui 2026-03-24 4/200 2026-03-24 22:59 by barlinike
[¿¼ÑÐ] ʳƷר˶ һ־Ը˫һÁ÷ 328 +3 xiaom99 2026-03-21 4/200 2026-03-24 21:20 by lailaisimei
[¿¼ÑÐ] 0854AI CV·½ÏòÕÐÊÕµ÷¼Á +3 ÕÂСÓã567 2026-03-23 3/150 2026-03-24 20:25 by Íô£¡£¿£¡
[¿¼ÑÐ] ²ÄÁÏר˶ÕÒµ÷¼Á +5 ¹þ¹þ¹þºðºðºð¹þ 2026-03-23 5/250 2026-03-24 19:07 by ÁËÁËÁËÁË¡£¡£
[¿¼ÑÐ] ²ÄÁÏר˶331Çóµ÷¼Á +4 Ïʵ±Å£ 2026-03-24 4/200 2026-03-24 15:58 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸¹þ¹¤´ó£¬085400£¬320£¬Çóµ÷¼Á +3 gdlf9999 2026-03-24 3/150 2026-03-24 10:08 by ²«»÷518
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉÂʦ´óÉúÎïѧ071000£¬298·Ö£¬Çóµ÷¼Á +3 SYA£¡ 2026-03-23 3/150 2026-03-23 19:09 by macy2011
[¿¼ÑÐ] 0854µç×ÓÐÅÏ¢Çóµ÷¼Á 324 +3 Promise-jyl 2026-03-23 3/150 2026-03-23 13:43 by wangkm
[¿¼ÑÐ] 263Çóµ÷¼Á +6 yqdszhdap£­ 2026-03-22 9/450 2026-03-23 12:57 by yqdszhdap£­
[¿¼ÑÐ] ÇóÀÏʦÊÕÎÒ +3 zzh16938784 2026-03-23 3/150 2026-03-23 12:56 by ztnimte
[¿¼ÑÐ] 308Çóµ÷¼Á +3 īīĮ 2026-03-21 3/150 2026-03-22 16:54 by i_cooler
[¿¼ÑÐ] ѰÕÒµ÷¼Á +4 ¾óǿâ? 2026-03-21 4/200 2026-03-22 16:14 by ľÍÐζ¶
[¿¼ÑÐ] 354Çóµ÷¼Á +7 Tyoumou 2026-03-18 10/500 2026-03-22 11:11 by ÈËÀ´Ê¢
[¿¼ÑÐ] ²ÄÁÏѧ˶333Çóµ÷¼Á +3 ±±µÀÏï 2026-03-18 3/150 2026-03-21 18:17 by ѧԱ8dgXkO
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á +5 ÊØºòϦÑôCF 2026-03-18 5/250 2026-03-21 01:06 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÄÏʦ´ó 070300£¨»¯Ñ§£©304·ÖÇóµ÷¼Á +3 0703ÎäÜ·»ÛÑ©304 2026-03-18 3/150 2026-03-21 00:48 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸ËÕÖÝ´óѧ²ÄÁÏÇóµ÷¼Á£¬×Ü·Ö315£¨Ó¢Ò»£© +5 sbdksD 2026-03-19 5/250 2026-03-20 22:10 by luoyongfeng
[¿¼ÑÐ] 320Çóµ÷¼Á0856 +3 ²»ÏëÆðÃû×Ö112 2026-03-19 3/150 2026-03-19 22:53 by ѧԱ8dgXkO
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û